SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Flannery O'Connor Synthetic CCD

PatientFlannery O'Connor
Date of birth2001-03-25
IdentifiersMRN HR-ML046-SYN; SSN (made up) 000-46-1853
Document date2026-11-01
AuthorAugusta Pemberton-Diallo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Primary care visit for joint pain and swelling, fevers, fatigue, a facial rash, and protein in the urine in a writer of 25. Concerns: Painful, swollen hands and knees, fevers, tiredness, and a rash on her face, for three months; Wants a plain, complete answer about what is wrong, told to her directly, and asks that it not be shared with anyone she has not named; Afraid of losing her writing mornings to illness or treatment. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth up to three times a day as needed for joint pain, no more than 3000 mg a dayTwo tablets up to every 8 hours as neededOral route2026-04-13activeS
Hydroxychloroquine sulfate 300 mg oral tablet, one tablet by mouth once daily (5 mg/kg of actual body weight), long termOne tablet once dailyOral route2026-04-22activeS
Losartan potassium 25 mg oral tablet, one tablet by mouth once daily, for proteinuria and blood pressureOne tablet once dailyOral route2026-04-22activeS
Methylprednisolone 500 mg intravenous infusion once daily for three daysOne infusion daily for three daysIntravenous route2026-04-29 to 2026-05-01completedS
Prednisone 5 mg oral tablet: 30 mg (six tablets) once daily from the day after the last pulse, reduced by 5 mg every two weeks to 10 mg, then to 5 mg a day or less by six monthsOnce daily, taperingOral route2026-04-29activeS
Mycophenolate mofetil 500 mg oral tablet, one tablet twice daily for one week, then two tablets (1000 mg) twice dailyTwo tablets twice dailyOral route2026-04-29activeS
Belimumab 200 mg/mL subcutaneous autoinjector: 400 mg (two injections) once weekly for four doses, then 200 mg once weeklyOnce weekly by self-injectionSubcutaneous route2026-04-29activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-04-29activeS
Nitrofurantoin (monohydrate/macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for seven daysOne capsule twice daily for seven daysOral route2026-06-15 to 2026-06-21completedS

Procedures

ProcedureDatesStatusEvidence
Ultrasound-guided percutaneous kidney biopsy: ISN/RPS class III (A) lupus nephritis, endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence, subendothelial deposits; no crescents, thrombotic microangiopathy, or interstitial fibrosis beyond 10 percent; no bleeding after the procedure2026-04-24 to 2026-04-24completedS
Insertion of a levonorgestrel 52 mg intrauterine system, her choice for contraception before mycophenolate; pregnancy test negative2026-04-28 to 2026-04-28completedS
Bone density scan (DXA) at the start of high-dose glucocorticoids: lumbar spine Z-score -0.4, femoral neck Z-score -0.2; normal for age2026-04-29 to 2026-04-29completedS
Baseline eye examination for hydroxychloroquine with dilated fundus examination, spectral-domain optical coherence tomography, and automated 10-2 visual fields: normal; yearly screening from five years of use2026-06-29 to 2026-06-29completedS

Immunizations

DateVaccineStatusEvidence
2025-10-10Influenza vaccine, 2025-2026 seasoncompletedS
2013-10-01HPV vaccine, 9-valent, series completed (dose 2 of 2)completedS
2019-05-14Tdap vaccinecompletedS
2026-04-22Pneumococcal conjugate vaccine PCV20completedS
2026-04-22Recombinant zoster vaccine, dose 1 of 2completedS
2026-07-27Recombinant zoster vaccine, dose 2 of 2completedS
2026-10-05Influenza vaccine, 2026-2027 seasoncompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
December 1949Month-long hospital stay with an operation for a floating kidneyD (CLM-0004)

Family History

RelativeConditionAge at deathEvidence
fatherSystemic lupus erythematosus, first diagnosed as rheumatoid arthritis; he died of it in 1941 at 4545D (CLM-0002)

Health Concerns

ConcernStatusEvidence
Painful, swollen hands and knees, fevers, tiredness, and a rash on her face, for three monthsactiveS
Wants a plain, complete answer about what is wrong, told to her directly, and asks that it not be shared with anyone she has not namedactiveS
Afraid of losing her writing mornings to illness or treatmentactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 12.8 on 2026-10-26; Leukocytes [#/volume] in Blood by Automated count 7.9 on 2026-06-15; Lymphocytes [#/volume] in Blood by Automated count 1.2 on 2026-10-26; Platelets [#/volume] in Blood by Automated count 236 on 2026-10-26; Creatinine [Mass/volume] in Serum or Plasma 0.8 on 2026-06-15; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 101 on 2026-10-26; Potassium [Moles/volume] in Serum or Plasma 4.6 on 2026-06-15; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2026-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 on 2026-10-26; Erythrocyte [Sedimentation Rate] in Blood by Westergren method 52 on 2026-04-13; C reactive protein [Mass/volume] in Serum or Plasma 0.6 on 2026-04-13; Protein/Creatinine [Mass Ratio] in Urine 0.35 on 2026-10-26; Erythrocytes [#/area] in Urine sediment by Microscopy high power field 2 on 2026-10-26; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-10-26; Pain severity - 0-10 verbal numeric rating [Score] - Reported 0 on 2026-10-26; Nuclear Ab [Titer] in Serum by Immunofluorescence 640 on 2026-04-22; DNA double strand Ab [Units/volume] in Serum 38 on 2026-10-26; Smith extractable nuclear Ab [Units/volume] in Serum 42 on 2026-04-22; Complement C3 [Mass/volume] in Serum or Plasma 96 on 2026-10-26; Complement C4 [Mass/volume] in Serum or Plasma 18 on 2026-10-26; Cardiolipin IgG Ab [Units/volume] in Serum by Immunoassay 6 on 2026-04-22; Cardiolipin IgM Ab [Units/volume] in Serum by Immunoassay 4 on 2026-04-22; Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum 3 on 2026-04-22; Beta 2 glycoprotein 1 IgM Ab [Units/volume] in Serum 2 on 2026-04-22; dRVVT/dRVVT W excess phospholipid (screen to confirm ratio) 1.04 on 2026-04-22; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 36 on 2026-07-27; DXA Lumbar spine [Z-score] Bone density -0.4 on 2026-04-29; DXA Femur [Z-score] Bone density -0.2 on 2026-04-29; Cholesterol [Mass/volume] in Serum or Plasma 212 on 2026-07-27; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 2026-07-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 128 on 2026-07-27; Triglyceride [Mass/volume] in Serum or Plasma 130 on 2026-07-27; Hemoglobin A1c/Hemoglobin.total in Blood 5.3 on 2026-07-27; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-05; Total score [AUDIT-C] 1 on 2026-10-05 [S]

Strengths and supports: Strengths: a sharp, ironic sense of humor and a steady religious faith; supports: friends and a writing community; she prefers to keep her health out of conversations about her work [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Pain and swelling of the small joints of both hands, the wrists, and the knees for three months, with an hour of morning stiffness, evening fevers to 38 °C, fatigue, and a red rash over the cheeks and nose after sun; told elsewhere it might be rheumatoid arthritis; cause to be establishedresolvedconfirmed M25.50S — Synthetic presenting concern at the index visit, superseded by the diagnosis of systemic lupus erythematosus at the second visit; joint pain in 1950 with suspected rheumatoid arthritis is documented (D).
Protein and blood in the urine: protein-to-creatinine ratio 1.6 g/g and 18 red cells per high-power field, with normal creatinine; cause to be establishedresolvedconfirmed R80.9S — Synthetic presenting finding at the index visit, superseded by the kidney biopsy diagnosis at the third visit.
Systemic lupus erythematosus, classified by the EULAR/ACR criteria (ANA 1:640 homogeneous; score 32 before the biopsy): inflammatory arthritis, acute cutaneous lupus (malar rash), fever, leukopenia with lymphopenia, mild thrombocytopenia, low C3 and C4, anti-dsDNA and anti-Sm positive; antiphospholipid antibodies and lupus anticoagulant negativeactiveconfirmed M32.19S — Synthetic modern diagnosis and results; her systemic lupus erythematosus, diagnosed in Atlanta in late 1950 or early 1951, is documented (D), but no finding from her lifetime is used.
Lupus nephritis, ISN/RPS class III (A), focal proliferative, on kidney biopsy: endocapillary proliferation in 9 of 30 glomeruli, activity index 6 of 24, chronicity index 1 of 12, full-house immunofluorescence; no thrombotic microangiopathy; urine protein-to-creatinine ratio 1.8 g/g; normal kidney functionactiveconfirmed M32.14S — Synthetic biopsy result and class; kidney involvement is documented at the end of her life, but no kidney finding from her lifetime is used.
Long-term glucocorticoid treatment for lupus nephritis, tapering to 5 mg a day or lessactiveconfirmed Z79.52S — Synthetic treatment status; the documented steroid harm in her life is the reason the episode keeps glucocorticoids low.
Long-term mycophenolate mofetil, with belimumab, for lupus nephritis; bone and infection protection in placeactiveconfirmed Z79.624S — Synthetic treatment status.
Levonorgestrel intrauterine system for highly effective contraception during mycophenolate treatmentactiveconfirmed Z97.5S — Synthetic contraception, chosen by the patient.
Acute cystitis on mycophenolate, belimumab, and prednisone 15 mg: two days of burning, frequency, and urgency without fever or flank pain; urine culture grew Escherichia coli sensitive to nitrofurantoin; resolved with seven days of nitrofurantoinresolvedconfirmed N30.00S — Synthetic common infection in an immunosuppressed young woman; coded without hematuria because the persistent hematuria is from her nephritis.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-13Hemoglobin [Mass/volume] in Blood11g/dL12-15.5 g/dLLowS
2026-04-13Leukocytes [#/volume] in Blood by Automated count3.310*3/uL4-11 10*3/uLLowS
2026-04-13Lymphocytes [#/volume] in Blood by Automated count0.810*3/uL1-4.8 10*3/uLLowS
2026-04-13Platelets [#/volume] in Blood by Automated count13810*3/uL150-400 10*3/uLLowS
2026-04-13Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1.1 mg/dLNormalS
2026-04-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-13Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
2026-04-13Albumin [Mass/volume] in Serum or Plasma3.3g/dL3.5-5 g/dLLowS
2026-04-13Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L<=33 U/LNormalS
2026-04-13Erythrocyte [Sedimentation Rate] in Blood by Westergren method52mm/h<=20 mm/hHighS
2026-04-13C reactive protein [Mass/volume] in Serum or Plasma0.6mg/dL<=0.5 mg/dLHighS
2026-04-13Protein/Creatinine [Mass Ratio] in Urine1.6g/g<=0.2 g/gHighS
2026-04-13Erythrocytes [#/area] in Urine sediment by Microscopy high power field18/[HPF]<=2 /[HPF]HighS
2026-04-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
2026-04-13Pain severity - 0-10 verbal numeric rating [Score] - Reported6{score}S
2026-04-22Nuclear Ab [Titer] in Serum by Immunofluorescence640{titer}Negative at 1:40 or less; the EULAR/ACR entry criterion is 1:80 or higherHighS
2026-04-22DNA double strand Ab [Units/volume] in Serum186[IU]/mL<=29 [IU]/mLHighS
2026-04-22Smith extractable nuclear Ab [Units/volume] in Serum42U/mL<=19 U/mLHighS
2026-04-22Complement C3 [Mass/volume] in Serum or Plasma62mg/dL90-180 mg/dLLowS
2026-04-22Complement C4 [Mass/volume] in Serum or Plasma8mg/dL10-40 mg/dLLowS
2026-04-22Cardiolipin IgG Ab [Units/volume] in Serum by Immunoassay6U/mL<=20 U/mLNormalS
2026-04-22Cardiolipin IgM Ab [Units/volume] in Serum by Immunoassay4U/mL<=20 U/mLNormalS
2026-04-22Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum3U/mL<=20 U/mLNormalS
2026-04-22Beta 2 glycoprotein 1 IgM Ab [Units/volume] in Serum2U/mL<=20 U/mLNormalS
2026-04-22dRVVT/dRVVT W excess phospholipid (screen to confirm ratio)1.04{ratio}<=1.2NormalS
2026-04-22Protein/Creatinine [Mass Ratio] in Urine1.8g/g<=0.2 g/gHighS
2026-04-22Erythrocytes [#/area] in Urine sediment by Microscopy high power field22/[HPF]<=2 /[HPF]HighS
2026-04-22Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1.1 mg/dLNormalS
2026-04-22Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-29Hemoglobin [Mass/volume] in Blood11.2g/dL12-15.5 g/dLLowS
2026-04-29Leukocytes [#/volume] in Blood by Automated count3.610*3/uL4-11 10*3/uLLowS
2026-04-29Lymphocytes [#/volume] in Blood by Automated count0.910*3/uL1-4.8 10*3/uLLowS
2026-04-29Platelets [#/volume] in Blood by Automated count15110*3/uL150-400 10*3/uLNormalS
2026-04-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L<=33 U/LNormalS
2026-04-2925-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma26ng/mL30-100 ng/mLLowS
2026-04-29DXA Lumbar spine [Z-score] Bone density-0.4{Z-score}Z-score above -2.0 is within the expected range for ageNormalS
2026-04-29DXA Femur [Z-score] Bone density-0.2{Z-score}Z-score above -2.0 is within the expected range for ageNormalS
2026-07-27Hemoglobin [Mass/volume] in Blood12.1g/dL12-15.5 g/dLNormalS
2026-07-27Leukocytes [#/volume] in Blood by Automated count5.210*3/uL4-11 10*3/uLNormalS
2026-07-27Lymphocytes [#/volume] in Blood by Automated count110*3/uL1-4.8 10*3/uLNormalS
2026-07-27Platelets [#/volume] in Blood by Automated count21210*3/uL150-400 10*3/uLNormalS
2026-07-27Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1.1 mg/dLNormalS
2026-07-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-27Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-07-27Albumin [Mass/volume] in Serum or Plasma3.8g/dL3.5-5 g/dLNormalS
2026-07-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L<=33 U/LNormalS
2026-07-27Protein/Creatinine [Mass Ratio] in Urine0.9g/g<=0.2 g/gHighS
2026-07-27Erythrocytes [#/area] in Urine sediment by Microscopy high power field6/[HPF]<=2 /[HPF]HighS
2026-07-27DNA double strand Ab [Units/volume] in Serum72[IU]/mL<=29 [IU]/mLHighS
2026-07-27Complement C3 [Mass/volume] in Serum or Plasma84mg/dL90-180 mg/dLLowS
2026-07-27Complement C4 [Mass/volume] in Serum or Plasma13mg/dL10-40 mg/dLNormalS
2026-07-2725-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma36ng/mL30-100 ng/mLNormalS
2026-07-27Cholesterol [Mass/volume] in Serum or Plasma212mg/dL<=199 mg/dLHighS
2026-07-27Cholesterol in HDL [Mass/volume] in Serum or Plasma58mg/dL>=50 mg/dLNormalS
2026-07-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation128mg/dL<=99 mg/dLHighS
2026-07-27Triglyceride [Mass/volume] in Serum or Plasma130mg/dL<=149 mg/dLNormalS
2026-07-27Hemoglobin A1c/Hemoglobin.total in Blood5.3%<=5.6%NormalS
2026-07-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-07-27Pain severity - 0-10 verbal numeric rating [Score] - Reported1{score}S
2026-10-26Hemoglobin [Mass/volume] in Blood12.8g/dL12-15.5 g/dLNormalS
2026-10-26Leukocytes [#/volume] in Blood by Automated count5.610*3/uL4-11 10*3/uLNormalS
2026-10-26Lymphocytes [#/volume] in Blood by Automated count1.210*3/uL1-4.8 10*3/uLNormalS
2026-10-26Platelets [#/volume] in Blood by Automated count23610*3/uL150-400 10*3/uLNormalS
2026-10-26Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1.1 mg/dLNormalS
2026-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-26Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-10-26Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-10-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L<=33 U/LNormalS
2026-10-26Protein/Creatinine [Mass Ratio] in Urine0.35g/g<=0.2 g/gHighS
2026-10-26Erythrocytes [#/area] in Urine sediment by Microscopy high power field2/[HPF]<=2 /[HPF]NormalS
2026-10-26DNA double strand Ab [Units/volume] in Serum38[IU]/mL<=29 [IU]/mLHighS
2026-10-26Complement C3 [Mass/volume] in Serum or Plasma96mg/dL90-180 mg/dLNormalS
2026-10-26Complement C4 [Mass/volume] in Serum or Plasma18mg/dL10-40 mg/dLNormalS
2026-10-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
2026-10-26Pain severity - 0-10 verbal numeric rating [Score] - Reported0{score}S
2026-06-15Leukocytes [#/volume] in Blood by Automated count7.910*3/uL4-11 10*3/uLNormalS
2026-06-15Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1.1 mg/dLNormalS
2026-06-15Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
2026-10-05Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-10-05Total score [AUDIT-C]1{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-04-13Body height168cmS
2026-04-13Body weight60kgS
2026-04-13Body mass index (BMI) [Ratio]21.3kg/m2S
2026-04-13Systolic blood pressure138mm[Hg]S
2026-04-13Diastolic blood pressure86mm[Hg]S
2026-04-13Heart rate96/minS
2026-04-13Respiratory rate16/minS
2026-04-13Body temperature37.9CelS
2026-04-13Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-04-22Body height168cmS
2026-04-22Body weight59.6kgS
2026-04-22Body mass index (BMI) [Ratio]21.1kg/m2S
2026-04-22Systolic blood pressure136mm[Hg]S
2026-04-22Diastolic blood pressure84mm[Hg]S
2026-04-22Heart rate92/minS
2026-04-22Respiratory rate16/minS
2026-04-22Body temperature37.6CelS
2026-04-22Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-04-29Body height168cmS
2026-04-29Body weight59.8kgS
2026-04-29Body mass index (BMI) [Ratio]21.2kg/m2S
2026-04-29Systolic blood pressure128mm[Hg]S
2026-04-29Diastolic blood pressure80mm[Hg]S
2026-04-29Heart rate84/minS
2026-04-29Respiratory rate14/minS
2026-04-29Body temperature37CelS
2026-04-29Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-07-27Body height168cmS
2026-07-27Body weight63.4kgS
2026-07-27Body mass index (BMI) [Ratio]22.5kg/m2S
2026-07-27Systolic blood pressure122mm[Hg]S
2026-07-27Diastolic blood pressure78mm[Hg]S
2026-07-27Heart rate76/minS
2026-07-27Respiratory rate14/minS
2026-07-27Body temperature36.7CelS
2026-07-27Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-10-26Body height168cmS
2026-10-26Body weight62kgS
2026-10-26Body mass index (BMI) [Ratio]22kg/m2S
2026-10-26Systolic blood pressure118mm[Hg]S
2026-10-26Diastolic blood pressure76mm[Hg]S
2026-10-26Heart rate72/minS
2026-10-26Respiratory rate14/minS
2026-10-26Body temperature36.6CelS
2026-10-26Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-06-15Body height168cmS
2026-06-15Body weight62.4kgS
2026-06-15Body mass index (BMI) [Ratio]22.1kg/m2S
2026-06-15Systolic blood pressure124mm[Hg]S
2026-06-15Diastolic blood pressure78mm[Hg]S
2026-06-15Heart rate84/minS
2026-06-15Respiratory rate14/minS
2026-06-15Body temperature37.3CelS
2026-06-15Oxygen saturation in Arterial blood by Pulse oximetry99%S
2026-10-05Body height168cmS
2026-10-05Body weight62.2kgS
2026-10-05Body mass index (BMI) [Ratio]22kg/m2S
2026-10-05Systolic blood pressure116mm[Hg]S
2026-10-05Diastolic blood pressure74mm[Hg]S
2026-10-05Heart rate70/minS
2026-10-05Respiratory rate14/minS
2026-10-05Body temperature36.6CelS
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
2026-04-13Primary care visit for joint pain and swelling, fevers, fatigue, a facial rash, and protein in the urine in a writer of 25finishedS
2026-04-22Diagnosis of systemic lupus erythematosus with the rheumatology consultation the same day; vaccinations before immunosuppressionfinishedS
2026-04-29Kidney biopsy result: class III lupus nephritis; start of pulse methylprednisolone, prednisone, mycophenolate, and belimumabfinishedS
2026-07-27Three-month response assessment for lupus nephritis and glucocorticoid taperfinishedS
2026-10-26Six-month response assessment: complete renal response; prednisone 5 mg; pregnancy planningfinishedS
2026-06-15Same-day sick visit for bladder symptoms on immunosuppressionfinishedS
2026-10-05Adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Inflammatory arthritis with fever, rash, cytopenias, and an abnormal urine: blood count, chemistry, ESR and CRP, urine microscopy and protein-to-creatinine ratio today; ANA, anti-dsDNA, anti-Sm, complements, and antiphospholipid antibodies; no NSAIDs with protein in the urinecompletedGL-EULAR-ACR-CRIT-2019, GL-ACR-LN-2024S
Rheumatology consultation within ten days, to confirm the diagnosis, stage organ involvement, and plan treatment with hercompletedGL-EULAR-SLE-2023S
Disclosure: every result explained to her directly and in plain words, with a written copy; her health shared only with the people she namescompletedGL-EULAR-SLE-2023S
Sun protection: broad-spectrum sunscreen SPF 50 or higher, a wide-brimmed hat, and shade in the middle of the daycompletedGL-EULAR-SLE-2023S
Hydroxychloroquine 300 mg daily (5 mg/kg) for every patient with lupus, long term, with a baseline eye examination within the first year and yearly screening after five yearscompletedGL-EULAR-SLE-2023, GL-AAO-HCQ-2016S
Kidney biopsy for proteinuria above 0.5 g/g with an active sediment, to class the nephritis before treatmentcompletedGL-ACR-LN-2024S
Vaccinations before immunosuppression: PCV20 and recombinant zoster dose 1 now, zoster dose 2 after one to two months, seasonal influenza and COVID-19; no live vaccines on immunosuppression; hepatitis B, hepatitis C, and HIV screeningcompletedGL-ACR-VAX-2022, GL-CDC-IMZ-MC-2026S
Angiotensin receptor blocker (losartan) for proteinuria and blood pressure, target below 130/80 mmHg, with potassium and creatinine two to four weeks after startingcompletedGL-ACR-LN-2024, GL-CMID-2026S
Contraception before mycophenolate: highly effective method of her choice (levonorgestrel intrauterine system); pregnancy test before starting; pregnancy planning later for at least six months of quiet disease on pregnancy-compatible medicinescompletedGL-ACR-REPRO-2020, GL-FDA-MMF-2026S
Class III lupus nephritis: methylprednisolone 500 mg daily for three days, then prednisone 30 mg tapered to 5 mg a day or less by six months; mycophenolate mofetil 2 g a day with belimumab, continued for three to five years after a complete response; blood counts weekly for the first month, twice monthly for the next two, then monthly; urine protein-to-creatinine ratio, urine sediment, creatinine, anti-dsDNA, and complements every three monthscompletedGL-ACR-LN-2024, GL-EULAR-SLE-2023, GL-FDA-MMF-2026, GL-FDA-BELIMUMAB-2026S
Bone protection on glucocorticoids: baseline DXA, vitamin D3 and calcium from food, weight-bearing exercise; report new hip, groin, or knee pain at once so avascular necrosis can be looked for with MRIcompletedGL-ACR-GIOP-2022, GL-EULAR-SLE-2023S
Cardiovascular risk: blood pressure at every visit, lipids and HbA1c at three months on glucocorticoids, no smoking, activity, and a lower glucocorticoid dosecompletedGL-EULAR-SLE-2023S
Writing life: treatment visits and infusions booked in the afternoons, belimumab self-injected at home, fatigue managed with graded activity and sleep; her illness kept out of conversations about her work unless she chooses otherwisecompletedGL-EULAR-SLE-2023S

Goals

GoalTargetStatusOutcomeProvenance
Establish the diagnosis within two weeks and hear it directly, in plain words2026-04-22completedTold directly at nine days that she has systemic lupus erythematosus, with the reasons and a written summaryS
Renal response: urine protein-to-creatinine ratio halved by three months and below 0.5 g/g with stable kidney function by six to twelve months2026-10-26completedRatio 1.8 at diagnosis, 0.9 at three months, 0.35 at six months, a complete response; creatinine 0.8 throughoutS
Prednisone 5 mg a day or less by six months, with withdrawal considered later2026-10-26completed5 mg a day at six monthsS
Write at least four mornings a week through treatment2026-12-31activeWriting five mornings a week by three monthsS
No unplanned pregnancy on mycophenolate; plan any pregnancy for a time of quiet disease on compatible medicines2026-12-31activeIntrauterine system in place; pregnancy planning discussedS

Functional Status

Mental Status